0.4396

0.54% -0.0024

After Hours: .4396

NeuBase Therapeutics Inc (NBSE)

Overview News Price History Discussions Forecast Stock Split

NeuBase Therapeutics Inc stock is currently priced at $0.4396, with a 24-hour trading volume of 72,169. It has seen a -0.54% decreased in the last 24 hours and a -8.19% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.4397 pivot point. If it approaches the $0.4303 support level, significant changes may occur.

Previous Close:

$0.442

Open:

$0.43

24h Volume:

72,169

Market Cap:

$1.65M

Revenue:

Net Income/Loss:

$-13.73M

P/E Ratio:

-0.0371

EPS:

-11.84

Net Cash Flow:

$-14.85M

1W Performance:

+2.23%

1M Performance:

-8.19%

6M Performance:

-30.64%

1Y Performance:

+240.78%

1D Range:

$0.412

$0.45

52W Range:

$0.1282

$4.44

NeuBase Therapeutics Inc Stock (NBSE) Company Profile

Name

NeuBase Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

412 763 3350

Address

350 Technology Drive, Suite 421, Pittsburgh, PA

Employee

Twitter

@NeuBaseInc

Next Earnings Date

2024-05-13

Latest SEC Filings

NBSE's Discussions on Twitter

NeuBase Therapeutics Inc Stock (NBSE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jun-16-20	Initiated	RBC Capital Mkts	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Nov-21-19	Initiated	Oppenheimer	Outperform
Sep-24-19	Initiated	BTIG Research	Buy

View All

NeuBase Therapeutics Inc Stock (NBSE) Latest News

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February

Benzinga

Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket

Benzinga

NeuBase Therapeutics Inc Stock (NBSE) Financials Data

NeuBase Therapeutics Inc (NBSE) Net Income 2024

NBSE net income (TTM) was -$13.73 million for the quarter ending September 30, 2023, a +59.35% increase year-over-year.

NeuBase Therapeutics Inc (NBSE) Cash Flow 2024

NBSE recorded a free cash flow (TTM) of -$14.85 million for the quarter ending September 30, 2023, a +49.65% increase year-over-year.

NeuBase Therapeutics Inc (NBSE) Earnings per Share 2024

NBSE earnings per share (TTM) was -$7.70 for the quarter ending September 30, 2023, a +62.98% growth year-over-year.

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.